Apple App Store Ban Harms Canopy Growth (TSX:WEED) Stock

The Apple ban on vaping apps harms Canopy Growth Corp (TSX:WEED)(NYSE:CGC), as it unveiled cannabis 2.0 vape pens and cartridges at a high-profile launch event.

| More on:
Economic Turbulence

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Health concerns over vaping are impacting cannabis stocks more than the industry would like. Top smartphone producer and popular dividend payer Apple has barred over 180 mobile applications from the Apple App Store. Apple removed the apps last month after substantial news coverage followed over 2,200 vaping-related lung illnesses and nearly 50 deaths.

Apple controls about 19% of the smartphone market, according to data provided by Gartner and Motley Fool contributor James Brumley. Moreover, Apple users tend to have a higher income than many other smartphone owners. Thus, the Apple App ban is set to reduce the digital appeal of cannabis vaping products in a critical market.

The Apple ban on vaping apps harms Canopy Growth (TSX:WEED)(NYSE:CGC), as it unveiled cannabis 2.0 vape pens and cartridges at a high-profile launch event last week. Canopy Growth’s Cannabis 2.0 portfolio expects to be a big moneymaker, something Canopy Growth shareholders desperately need to turn around the stock’s negative $1.22 billion levered free cash flow.

Canopy Growth shareholders won’t see high returns anytime soon

Levered free cash flow is money available for the company to return to shareholders as dividend interest or through capital gains. Negative levered free cash flow typically signals to investors that the company faces a long time horizon before it can return profits to shareholders.

Although not a definitive relationship, a negative free cash flow indicates future stock price depreciation. In the case of Canopy Growth, Canadian investors should take caution with this stock. Speculative trading has distorted the market value of the shares, leading to a nearly 50% loss in the stock price over the past 52 weeks.

It may not be the safest move to build significant positions in Canopy Growth stock at the share price of $24 at the time of writing, but stock market investors should still keep an eye on the stock. There is a lot of exciting news coming out about the marijuana stocks, with some reports rousing investors more than other announcements.

U.S. SAFE bill overshadows negative vaping headlines

Thus far, shareholders haven’t reacted too strongly to the negative headlines about the marijuana industry’s highest-margin product: cannabis extracts used in vaping devices. News of the vaping lung disease has taken a backseat to a crucial legislative win in the United States.

The market has been excited over the passage of the U.S. SAFE banking act in the House of Representatives. The SAFE bill will shield financial institutions from legal harm when doing business with cannabis dispensaries in the United States.

Not only is marijuana still illegal at the federal level in the U.S., but banks must prevent and report on money laundering. Investors expect the passage of the SAFE bill to boost export opportunities for Canopy Growth and other pot stocks.

Foolish takeaway

Now is a great time to pick up shares in pot stocks for your Tax-Free Savings Account or Registered Retirement Savings Plan — as long as it isn’t Canopy Growth. Considering the high negative-levered free cash flow, Canopy Growth is still overpriced compared to many peers on the Toronto Stock Exchange.

High-growth industries like cannabis are going to get a boost soon, so look for cheap marijuana stocks with positive free cash flow. Shares in inexpensive cannabis stocks with less debt will turn a profit faster and return interest to shareholders sooner than Canopy Growth.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Debra Ray has the following options: short January 2020 $15 puts on Canopy Growth. David Gardner owns shares of Apple. The Motley Fool owns shares of and recommends Apple. The Motley Fool recommends Gartner.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »